HSE begins talks on CF drug Orkambi
News relief to patients with cystic fibrosis and families
Negotiations between the state and the manufacturer of cystic fibrosis drug Orkambi have finally begun.
The news will be a relief to patients with cystic fibrosis and their families, who had begun to question why the health service had yet to decide whether it would seek to provide the drug – at a cost of €160,000 per patient per year.
The National Centre for Pharmacoeconomics (NCPE) recommended against funding the drug in June, but that...
Subscribe from just €1 for the first month!
What's Included
With any subscription you will have access to
-
Unlimited multi-device access to our iPad, iPhone and Android Apps
-
Unlimited access to our eReader library
-
Exclusive daily insight and opinion seven days a week
-
Create alerts to never miss a subject that matters to you
-
Get access to exclusive offers for subscribers on gifts and experiences
-
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Related Stories
Editorial: Our inability to agree on a model of healthcare in Ireland is unacceptable
The government is failing in its duties to provide a working healthcare system
HSE yet to cooperate with Sláintecare business case
There are concerns that the deadline for the business case, which concerns regionalisation plans, will be missed unless the HSE agrees to take part
Healthcare software developers claim they could cut waiting lists by 25%
The Irish Hospital Consultants Association has warned that the numbers waiting for either treatment or a consultation will soon increase to over one million patients
Tony O’Brien: The apparent slow collapse of Sláintecare deserves more than a shrug of the shoulders
Downplaying and media management dominated the government’s response to the resignation of Laura Magahy and Tom Keane from the Sláintecare programme
